Nitin Jain, MD

Department of Leukemia, Division of Cancer Medicine.
nitin jain.jpg.resize.810.1150.high
Nitin Jain, MD Department of Leukemia, Division of Cancer Medicine
Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He then moved to the United States and completed his Internal Medicine residency training at the Medical College of Wisconsin, Milwaukee, Wisconsin. He then completed a year of clinical fellowship in Leukemia at MD Anderson Cancer Center followed by another year of Leukemia research fellowship at the Memorial Sloan-Kettering Cancer Center in New York. He then pursued fellowship in Hematology/Oncology at the University of Chicago. He was then recruited as a faculty member in the Department of Leukemia at MD Anderson Cancer Center in 2012. Dr. Jain treats patients with acute and chronic leukemia with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Dr. Jain research interests focus on new drug development for patients with leukemia, especially CLL and ALL. Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, combination of ibrutinib and chemotherapy (iFCG regimen) in CLL, checkpoint inhibitors in CLL and Richter transformation, trial with JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, and off-the-self allogeneic CART in B-ALL. He has published papers in prominent journals including Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia Lymphoma, Leukemia Research and others. He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology and Merit Award from the American Society of Clinical Oncology (ASCO). He was ranked first at the national level in India in the medical school (AIIMS) entrance examination in the year 1997. He received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014 and 2016. He has served as a faculty on American Society of Hematology CRTI workshop for year 2017 and 2018. He is recipient of Sabin Family Foundation Award in 2018.